The latest research on Myriad Genetics trims the modeled fair value only slightly, from US$8.32 to US$8.12 per share, and aligns a new US$7 price target with expectations across the broader ...
The Street’s view on Castle Biosciences has shifted, with the consensus analyst price target moving from about US$46.00 to ...
Amazon has updated its large-screen Kindle Scribe ereader with a sleeker design and a slightly bigger screen, but not much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results